Janux Therapeutics, Inc.

Today, JANX trades at 13.98 USD.

For broader market analysis, dive into the technicals on the Janux Therapeutics, Inc. stock price chart and read the latest JANX news:
– JANX Q3'26 Earnings: EPS estimate is (0.47) USD
– Weekly Recap: Combination trial doses first patient and Q3 loss narrows
– Janux Therapeutics Price Target Raised to $27.00/Share From $26.00 by Truist Securities

Markets don't sleep, here's what's going on with JANX at the moment:
– JANX Q3'26 Earnings: EPS estimate is (0.47) USD
– Weekly Recap: Combination trial doses first patient and Q3 loss narrows
– Janux Therapeutics Price Target Raised to $27.00/Share From $26.00 by Truist Securities

See more updates in real-time with our News Flow.

Janux Therapeutics, Inc. is scheduled to release its next earnings report on Nov 10, 2026.

Why it matters:
– Key event: Earnings often drive significant price moves
– Market expectations: Traders watch revenue, EPS, and guidance vs forecasts
– Volatility spike: Price swings can increase before and after the release

How to use it:
– Track upcoming reports in the Earnings Calendar
– Compare actual results with analyst estimates
– Monitor price reaction and volume on Supercharts

JANX stock is 44.41% volatile and has beta coefficient of 1.69.

What it means:
– Volatility: Shows how much the price fluctuates over time
– Beta > 1: More volatile than the market
– Beta < 1: Less volatile, more stable

Important to know:
– Volatility can increase during earnings, news events, or market stress
– Large-cap stocks like JANX are typically less volatile than smaller companies

Track every detail on Janux Therapeutics, Inc. stock chart and check out the list of the most volatile stocks — is Janux Therapeutics, Inc. there?

To understand the JANX stock performance, it's worth checking price changes for various periods to get the full picture:
– 1 day — +9.78%
– 1 week — −1.65%
– 1 month — +6.72%

JANX all-time low was 5.65 USD (Nov 10, 2023), and its highest price is 71.71 USD (Dec 5, 2024). Find more dynamics in the Stock Heatmap and on the Janux Therapeutics, Inc. stock chart.

Janux Therapeutics, Inc. market capitalization is ‪1.08 B‬, representing the total value of all its outstanding shares (price × shares outstanding).

What it means:
– Market cap is one of the key ways to classify companies (large-cap, mid-cap, etc.)
– It reflects how investors value the company today
– It changes constantly with stock price movements

What to look at next:
– Market cap trends: Rising cap may signal growth and investor confidence; falling cap can reflect risk or downturns
– Price vs shares: Changes can come from Janux Therapeutics, Inc. stock price moves or share count (buybacks, issuance)
– Valuation ratios: Compare market cap with revenue and earnings
– Peer comparison: See how Janux Therapeutics, Inc. stacks up against other companies

The safest way to buy Janux Therapeutics, Inc. stocks is through a reliable broker. Create an account, fund it, and place a buy order.

You can trade JANX directly from TradingView:
– Choose a broker: Explore our supported trading partners and pick one that fits your needs
– Compare options: View available brokers side by side to evaluate fees and features
– Connect your account: Open Supercharts, click “Trade”, select your broker, and log in
– Start trading: Place orders without leaving the chart

Tip: If you’re new to trading, try paper trading first — it lets you practice strategies in real market conditions without risking funds.

As of Nov 9, 2026, the company has 109 employees.

Why traders follow this data:
– Company scale: Employee count reflects the size and global reach of the business
– Operational footprint: Higher headcount often indicates broader product lines, retail presence, or services
– Trend signal: Changes over time can reflect hiring growth, restructuring, or efficiency improvements

See our rating of the largest employers to find more opportunities.

Janux Therapeutics, Inc. stock ticker depends on the exchange where it’s listed. On the NASDAQ, its primary exchange, Janux Therapeutics, Inc. stocks trade under the symbol JANX.

About tickers:
– Unique identifiers: A ticker is a short code used to find and trade a stock
– Exchange-specific: The same company may have different tickers across exchanges
– Search shortcut: Used on trading platforms, charts, and screeners

Remember:
– Some companies have multiple listings
– Always check the exchange prefix to avoid confusion

Learn how to find your desired assets in our Symbol Search.

JANX earnings for the last quarter are −0.35 USD per share, whereas the estimation was −0.25 USD, resulting in a −39.28% surprise. The estimated earnings for the next quarter are −0.47 USD per share.

How to read financials:
– Compare actual vs estimates: Earnings beats or misses often drive price moves
– Watch market reaction: Price response matters as much as the numbers
– Look at forward guidance: Future estimates signal expected growth
– Track trends: Analyze results across multiple quarters, not just one

Follow other essential metrics in Janux Therapeutics, Inc. financials:
– Revenue growth: Shows business expansion
– Margins (operating, net): Reflect profitability and efficiency
– Free cash flow: Indicates real cash generation
– Debt levels: Impacts financial stability and risk

Janux Therapeutics, Inc. revenue for the last quarter amounts to ‪10.27 M‬ USD despite the estimated figure of ‪19.07 M‬ USD. In the next quarter revenue is expected to reach ‪8.03 M‬ USD.

How to read this data:
– Compare actual vs estimates: Revenue beats or misses can move the stock
– Watch market reaction: Price response shows how investors interpret results
– Look at growth: Compare with previous quarters and year-over-year data
– Track trends: One quarter matters less than consistent performance

Follow other essential metrics in Janux Therapeutics, Inc. financials:
– Earnings (EPS): Profitability per share
– Margins (gross, operating): Efficiency and cost control
– Free cash flow: Cash available after expenses

Yes, you can track Janux Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.

Use our Earnings Calendar to never miss important releases and spot opportunities early.

JANX net income for the last quarter is ‪−21.57 M‬ USD, while the quarter before that showed ‪−21.97 M‬ USD of net income which accounts for 1.83% change.

How to read this data:
– Track changes: Compare net income across quarters to spot trends
– Watch expectations: Compare with estimates to gauge performance
– Check margins: Net income reflects profitability after all expenses
– Look beyond one quarter: Consistency matters more than a single result

Follow other essential metrics in Janux Therapeutics, Inc. financials:
– Revenue: Overall business growth
– Earnings per share: Rising EPS over time often points to improving business performance
– Margins (gross, operating): Efficiency and cost control

No, Janux Therapeutics, Inc. does not currently pay dividends to its shareholders.

Instead of distributing profits as cash payments, the company may choose to reinvest earnings back into the business — for example, in growth, innovation, acquisitions, or debt reduction.

What to consider instead:
– Earnings growth: Is the company increasing profitability over time?
– Revenue expansion: Is the business scaling its operations?
– Free cash flow: Does it generate enough cash to potentially support future dividends?
– Share buybacks: Some companies return capital through repurchasing shares instead of dividends

JANX reached its all-time high of 71.71 USD on Dec 5, 2024. Its all-time low was 5.65 USD and was reached on Nov 10, 2023.

Explore the Janux Therapeutics, Inc. stock price chart to see more price history, and discover companies reaching new all-time highs and lows.

Janux Therapeutics, Inc. EBITDA is ‪−137.70 M‬ USD, with an EBITDA margin of ‪−1.56 K‬%.

EBITDA is a measure of core operating performance, showing how much profit the company generates from its main business activities before accounting for financing and accounting-related costs.

What it means:
– Operating strength: Helps assess profitability from core operations
– Efficiency signal: Rising EBITDA often reflects improving business performance
– Comparability: Useful for comparing companies with different capital structures

What to look at next in Janux Therapeutics, Inc. statements:
– Revenue growth: Shows whether the business is expanding
– Net income: Captures full profitability after all expenses
– Free cash flow: Shows actual cash generated
– Debt levels: Important when evaluating earnings quality